You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Baxter
Colorcon
Johnson and Johnson
Moodys

Last Updated: April 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for CRLX101

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for CRLX101?

CRLX101 is an investigational drug.

There have been 12 clinical trials for CRLX101. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2012.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are Cerulean Pharma Inc., National Cancer Institute (NCI), and University of Chicago.

There are sixty-one US patents protecting this investigational drug and five hundred and thirty-five international patents.

Recent Clinical Trials for CRLX101
TitleSponsorPhase
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide TreatmentNational Cancer Institute (NCI)Phase 2
Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1/Phase 2
Alternative Dosing for CRLX101 Alone, With Avastin and With mFOLFOX6 in Advanced Solid TumorsCerulean Pharma Inc.Phase 1

See all CRLX101 clinical trials

Clinical Trial Summary for CRLX101

Top disease conditions for CRLX101
Top clinical trial sponsors for CRLX101

See all CRLX101 clinical trials

US Patents for CRLX101

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CRLX101   Start Trial Cyclopropylamines as LSD1 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (Brentford, Middlesex, GB)   Start Trial
CRLX101   Start Trial Benzimidazole derivatives as PI3 kinase inhibitors GlaxoSmithKline LLC (Wilmington, DE)   Start Trial
CRLX101   Start Trial ICOS binding proteins GlaxoSmithKline Intellectual Property Development Limited (Brentford, Middlesex, GB)   Start Trial
CRLX101   Start Trial Benzimidazole derivatives as PI3 kinase inhibitors GLAXOSMITHKLINE LLC (Wilmington, DE)   Start Trial
CRLX101   Start Trial Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives Research Triangle Institute (Research Triangle Park, NC)   Start Trial
CRLX101   Start Trial 10,11-methylenedioxy camptothecins Research Triangle Institute (Research Triangle Park, NC)   Start Trial
CRLX101   Start Trial Preparation of water soluble camptothecin derivatives Glaxo Inc. (Research Triangle Park, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CRLX101

Drugname Country Document Number Estimated Expiration Related US Patent
CRLX101 Australia AU2012236868 2031-03-25   Start Trial
CRLX101 Brazil BR112013024502 2031-03-25   Start Trial
CRLX101 Canada CA2831143 2031-03-25   Start Trial
CRLX101 Chile CL2013002737 2031-03-25   Start Trial
CRLX101 China CN103857393 2031-03-25   Start Trial
CRLX101 Colombia CO6771447 2031-03-25   Start Trial
CRLX101 Costa Rica CR20130550 2031-03-25   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Baxter
Colorcon
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.